Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Melany Atkins

Diagnostic Radiology Fairfax, VA Medical Doctor

NPI 1518177278 CMS profile 548731

2722 Merrilee Dr Ste 230, Fairfax, VA 22031

Open in the dashboard

General payments

$77,325

128 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Melany Atkins of Fairfax, VA is reported in the CMS Open Payments database as having received $77,325 across 128 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Diagnostic Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $15,588 36
2024 General $18,583 18
2023 General $26,834 21
2022 General $6,626 16
2021 General $3,000 22
2020 General $5,595 6
2019 General $1,100 9

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Melany Atkins
  • Diagnostic Radiology median
  • Middle half of Diagnostic Radiology
  • National median

In program year 2025, general payments to Melany Atkins were reported at $15,588. Among 8,325 Diagnostic Radiology profiles paid that year, the median was $112 and the middle half received between $32 and $349.

Show as a table
Year Melany Atkins Diagnostic Radiology median Middle half National median
2019 $1,100 $108 $29–$318 $163
2020 $5,595 $65 $21–$252 $114
2021 $3,000 $92 $24–$292 $132
2022 $6,626 $104 $29–$294 $149
2023 $26,834 $110 $29–$337 $160
2024 $18,583 $113 $30–$356 $164
2025 $15,588 $112 $32–$349 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Ge Healthcare $59,384 63 payments
  2. HeartFlow, Inc. $14,128 34 payments
  3. Bayer HealthCare Pharmaceuticals Inc. $1,362 7 payments
  4. Siemens Medical Solutions USA, Inc. $1,091 12 payments
  5. Bayer Healthcare LLC $556 1 payment
  6. Edwards Lifesciences Corporation $309 5 payments
  7. Abbott Laboratories $289 2 payments
  8. Medtronic, Inc. $135 1 payment
  9. United Therapeutics Corporation $37 2 payments
  10. Guerbet LLC $34 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $48,897 18 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $20,117 16 payments
  3. Food and Beverage $4,889 83 payments
  4. Travel and Lodging $3,422 11 payments
Products named General payments · program years 2019–2025
  1. FFRct $14,057 32 payments
  2. NA $3,300 1 payment
  3. Adempas $1,269 3 payments
  4. Somatom Force $903 10 payments
  5. Edwards SAPIEN 3 Ultra Transcatheter Heart Valve $170 1 payment
  6. MITRACLIP $147 1 payment
  7. Mitra Clip system $142 1 payment
  8. Edwards SAPIEN 3 Transcatheter Heart Valve $139 4 payments
  9. COREVALVE EVOLUT R $135 1 payment
  10. SOMATOM Pro.Pulse $110 1 payment
  11. Other $404 9 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 64 billing codes

Paid by Medicare

$262,321

Of which drugs: $5,111

Medicare patients

2,059

Average age 75

Services billed

50,674

1,008 women, 1,051 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 51%
Arthritis 49%
Diabetes 32%
Heart failure 32%
Atrial fibrillation 30%
Chronic kidney disease 30%
Depression 22%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 526 46,962 $4,461
Injection, gadoteridol, (prohance multipack), per ml A9576 Office 14 345 $368
Injection, gadobutrol, 0.1 ml A9585 Office 16 680 $168

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Adempas
  • Bayer HealthCare Pharmaceuticals Inc. $51
$51 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

128 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Diagnostic Radiology in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record